The role of individual human cytochrpmes P450 in drug metabolism and clinical response
- 31 December 1992
- journal article
- review article
- Published by Elsevier BV in Trends in Pharmacological Sciences
- Vol. 13 (12), 434-439
- https://doi.org/10.1016/0165-6147(92)90140-2
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- A predictive model for substrates of cytochrome P450-debrisoquine (2D6)Chemical Research in Toxicology, 1992
- Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjectsPharmacogenetics, 1992
- Clinical implications of variable antiarrhythmic drug metabolismPharmacogenetics, 1992
- Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindredsPharmacogenetics, 1992
- Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9Biochemical and Biophysical Research Communications, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Genetic polymorphism of S-mephenytoin hydroxylationPharmacology & Therapeutics, 1989
- The polymorphic oxidation of beta-adrenoceptor antagonistsPharmacology & Therapeutics, 1989
- Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiaeBiochemistry, 1989
- Pharmacogenetics of tolbutamide metabolism in humansDiabetes, 1979